The U.S. Food and Drug Administration is giving notice that the agency is withdrawing the conditional approval for Paccal Vet-CA1 (paclitaxel for injection) at the request of the drug’s manufacturer, Oasmia Pharmaceutical AB. Paccal Vet-CA1 was intended to treat certain mammary and squamous cell carcinomas in dogs that have not received previous chemotherapy or radiation therapy. The conditional approval for Paccal Vet-CA1 is no longer in effect as of February 8, 2017. Paccal Vet-CA1 is now an unapproved animal drug with no legal marketing status and further sales of the drug are illegal.
No comments:
Post a Comment